The information disclosed in this section and elsewhere within HealthBeacon’s Investors Section of the website is in accordance with Rule 26 of the Euronext Growth Rules for Companies.  


Last Updated: 15 December 2021 


Description of the business 


HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The Company’s mission is to become the world’s leading digital therapeutics platform for injectable medications. 


The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools and artificial intelligence driven data analytics. The Company provides valuable insight to the Patients, Pharmaceutical, Specialty Pharmacy and Clinicians in bettering patient outcomes. 


The HealthBeacon Smart Sharps Bin is the world’s first US Food and Drug Administration cleared smart sharps bin. In addition, the HealthBeacon Companion App plays an important role in a patients at-home medication routine, increasing the likelihood of patients taking the drug at home by approximately 24-38%. 

The Company accesses the end patient through three distinct distribution models: (i) Patient Support Programmes; (ii) Direct to Consumer and (iii) Reimbursed Digital Therapeutic. 


The following are some key steps undertaken by the Company to achieve its mission: 

  • Generate long-term growth through a recurring revenue business model; 
  • Deploy more than 100k HealthBeacon Smart Sharps units in the near term; 
  • Expansion into the US market via Direct to Consumer (“DTC”) and Specialty Pharmacy Channel; and 
  • Building on its current blue chip client base. 


Board of Directors  

To read our directors’ biographies, see (here)


Corporate Governance and Board Committees 

HealthBeacon’s directors recognise the importance of high standards of corporate governance. To read our corporate governance and composition of the Board committees and responsibilities, see (here) 

Country of Incorporation & Main Country of Operation:  

The Company was incorporated in the Republic of Ireland (registered no. 530689) in July 2013, the Company re-registered as a PLC on the 6th of December 2021. The Company’s registered headquarters is Unit 20 Naas Road Business Park, Muirfield Drive, Naas Road, Dublin 12, D12 WD85, Ireland. 


Current Constitutional Documents: 

To read our Company Constitution, see (here) 



The Company is listed on the Euronext Growth (Dublin) from 15 December 2021. 


Admitted Securities see (here) 

Details of restrictions on the transfer of the Company’s admitted securities: 

There are no restrictions on the transferability of the Company’s shares other than certain lock-up agreements entered into between the Company, the Directors, members of senior management, certain shareholders and the Company’s Euronext Growth Listing Sponsor, Goodbody. 


Shareholder Information see (here) 

Issuer Notifications  

For notifications in the last 12 months, see (here) 

Information Document see (here) 


Corporate Governance Code 

The Board of HealthBeacon Limited recognises the importance of maintaining good corporate governance and has chosen to apply the Quoted Companies Alliance Corporate Governance Code, issued in April 2018 (the “QCA Code”). The Company discloses in this corporate governance statement (the “Corporate Governance Statement”) (and shall within its annual report and accounts disclose) how it complies with the QCA Code and, where it departs from the QCA Code, explains the reasons for doing so. For details of the Company’s Corporate Governance Code, see (here)   


Irish Takeover Rules 

The Company is subject to the Takeover Rules of the Irish Takeover Panel. 

The Takeover Rules comprise rules made by the Irish Takeover Panel under the powers granted to it by the 1997 Act and by the European Communities (Takeover Bids (Directive 2004/25/EC)) Regulations 2006, as amended (“Regulations”). 


The Panel is designated under the Regulations as the competent authority for the purpose of Article 4(1) of the Directive. 


The Regulations, which were made by the Minister for Enterprise, Trade and Employment, came into operation on 20 May 2006. 


Regulation 4(1) of the Regulations applies the 1997 Act, subject to the Regulations, to each company a takeover bid (as defined in the Regulations) in respect of which the Panel has jurisdiction to supervise under the Regulations. Under Regulation 4(3), references to a “relevant company” in the 1997 Act include references to each company a bid for which the Panel has jurisdiction to supervise. 


The Rules, of which there are 41, have been made principally to ensure that takeovers (including takeover bids as defined in the Regulations) and other relevant transactions comply with the principles (“General Principles”) set out in the Schedule to the 1997 Act. 


Advisors see (here)